Here are the 10-Q quarterly reports from Avalyn Pharma Inc. (AVLN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AVLN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVLN filings page.
Avalyn Pharma Inc. reported a net loss of $29.655 million for the three months ended September 30, 2026, compared with $23.584 million a year earlier. Quarterly research and development expense was $25.491 million, versus $22.089 million, while general and administrative expense was $7.603 million, versus $3.234 million. For the first nine months of 2026, net loss was $85.459 million and cash used in operating activities was $82.237 million.
At September 30, 2026, cash, cash equivalents and marketable securities totaled $386.6 million. Avalyn stated these funds would be sufficient for operating expenses and capital expenditures for at least 12 months from issuance of the statements. Its May 1, 2026 IPO sold 19,166,667 shares at $18.00 per share and generated approximately $316.6 million in net proceeds. The company borrowed $15.0 million under a term loan facility of up to $30.0 million, with an additional $15.0 million available through December 31, 2027; the loan matures June 30, 2030.
Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on inhaled therapies for rare respiratory diseases, reported higher operating losses as it advanced multiple clinical programs and strengthened its balance sheet. For the six months ended June 30, 2026, net loss was $55.8 million compared with $37.7 million a year earlier, driven mainly by increased research and development spending on lead candidates AP01 and AP02 and pipeline asset AP03, as well as higher public-company general and administrative costs.
Total operating expenses rose to $59.2 million, including $47.6 million of research and development and $11.6 million of general and administrative expenses. On May 1, 2026, Avalyn completed an IPO, issuing 19,166,667 shares at $18.00 per share for net proceeds of $316.6 million, and simultaneously converted all series of redeemable convertible preferred stock into 23,918,194 common shares. The company also drew $15.0 million under a Term Loan facility. As of June 30, 2026, Avalyn held cash, cash equivalents and marketable securities totaling $413.5 million, total assets of $425.4 million, and 44,333,095 shares of common stock outstanding, and stated that this liquidity is expected to fund operations into 2029.
Avalyn Pharma Inc. reported a larger net loss for the quarter ended March 31, 2026 as it increased investment in its pulmonary fibrosis pipeline. Net loss was $26.9 million compared with $17.5 million a year earlier, driven mainly by higher research and development spending on AP01 and AP02 and growing corporate costs.
Research and development expenses rose to $22.9 million and general and administrative expenses to $5.0 million, reflecting expanded clinical activity and headcount. Avalyn ended the quarter with $123.1 million in cash, cash equivalents and marketable securities and added a $15.0 million term loan facility draw. After the quarter, it completed an IPO raising about $316.1 million in net proceeds, and now expects its cash resources to fund operations into 2029.